PTC Gambles On Success With Emflaza; Says Price Revision Is Needed
Looking to become a therapeutic area leader in DMD, PTC pays $140m up front for Marathon's controversial Emflaza, but the biotech's stock price plummeted, indicating that investors don't share PTC's optimism.
You may also be interested in...
With $1.1bn in cash plus revenue from its existing commercial products and royalties from Roche’s sales of newly approved Evrysdi to invest in R&D, PTC Therapeutics may achieve profitability in 2023.
With three products now approved in Europe and/or the US for Duchenne Muscular Dystrophy, an FDA decision pending on PCT Therapeutics' ataluren and multiple companies exploring different approaches in preclinical and clinical studies, Scrip provides an overview of the development landscape and commercial results to date.
US FDA's Peripheral and Central Nervous System Drugs Advisory Committee to consider application, which PTC Therapeutics filed over protest.